TerminatedPhase 1

Effect of Oral Galactose on Focal Segmental Glomerulosclerosis (FSGS) Permeability Factor

Stopped: Study closed by Institutional Review Board

15 participantsStarted 2008-12

Plain-language summary

This study is a proof-of-concept clinical study designed to test the hypothesis that oral administration of galactose can lower the level of a circulating factor that increases glomerular permeability to albumin in patients with resistant FSGS.

Who can participate

Age range2 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Primary FSGS * Resistance to steroids and another immunosuppressive medication Exclusion Criteria: * Secondary FSGS

What they're measuring

Reduction in FSGS permeability factor

Timeframe: 28 days

Trial details

NCT IDNCT00816478

SponsorNorthwell Health

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2009-12

View on ClinicalTrials.gov More Focal Segmental Glomerulosclerosis trials